SMART Data Confirm Risk of CD4-guided Treatment Interruptions

Interruption of antiretroviral therapy is a potentially hazardous strategy associated with an increased risk of disease progression or death, according to data from the large international SMART (Strategies for Management of Antiretroviral Therapy) study.

AASLD 2006: Liver Transplantation in HIV Positive Patients

The Thomas E. Starzl Transplant Surgery State-of the-Art Lecture at this year’s American Association for the Study of Liver Diseases (AASLD) annual meeting was devoted to the outcomes following solid organ transplantation in HIV-infected recipients. The speaker, Peter G. Stock, MD, from the University of California at San Francisco, gave a very good update on the topic.


AIDS 2006: TNX-355 Produces Significant Reduction in HIV Viral Load at 48 Weeks

Data on several investigational anti-HIV drug candidates were presented at the XVI International AIDS Conference last week in Toronto, including the latest results from a study of Tanox’s investigational monoclonal antibody, TNX-355. TNX-355 is a recombinant human antibody that binds to domain 2 of the CD4 receptor, thereby blocking the entry of HIV into host cells.